Genenta Science (NASDAQ:GNTA) Stock, Quote.Headers.trade-ideas

Genenta Science

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADSK

AGIL

ANGH

ATGL

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATPC

CNTB

EDSA

GHRS

GNTA

GSX Techedu Inc. American Depositary Shares

GOTU

GYRE

HSCS

MIRA

PXMD

RVYL

SHOT

SPRC

TCON

THAR

URBN

Shares of Urban Outfitters, Inc. (NASDAQ: URBN) dipped during Wednesday’s session after the company reported third-quarter financial results.

Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Pre-Market Outlook

AKTX

ALLG

ANPC

ANVS

APGN

AREB

ARQQ

ASAN

AUUD

AYLA

BBIG

CDLX

CDRO

CLAQ

CLVS

CVNA

DICE

EVEX

GSHD

HYPR

IBRX

IDAI

IDYA

IMTX

INLX

KSPN

LCID

LPTX

LSAK

MEGL

MOGU

NRBO

NTCT

NUWE

PIXY

PYPD

RBBN

REBN

RGLS

RMED

RYTM

SGML

STRC

SWTX

TRDA

TUEM

VTNR

VTYX

WETG

YOSH

Gainers


	NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.


Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday

AZRE

SHPH

SPPI

Gainers


	Ventyx Biosciences, Inc.  (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.


Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday&#39;s Mid-Day Session

Genenta Science S.p.A. - American Depositary Shares

Genenta Science SPA

U.S. stocks traded slightly lower toward the end of trading, with the S&amp;P 500 edging lower on Thursday.
The Dow traded down 0.03% to 43,283.94 while the NASDAQ fell 0.05% to 20,021.98. The S&amp;P 500 also fell, dropping, 0.07% to 6,035.54.
Check This Out: <a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Industrials shares rose by 0.3% on Thursday.
In trading on Thursday, consumer discretionary shares dipped by 0.5%.
Top Headline
U.S. initial jobless claims fell by 1,000 from the previous week to a reading of 219,000 during the second week of December, compared to market estimates of 224,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares shot up 48% to $8.08. On Thursday, SEALSQ announced the launch of SEALQUANTUM.com Lab, a research hub designed to help businesses transition to quantum-safe encryption</li>
<li>Shares of SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>)got a boost, surging 117% to $0.4801 after the company announced it received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) shares were also up, gaining 75% to $2.50 after it reported a 43% year-on-year increase in November bookings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Neuphoria Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEUP#NASDAQ">NEUP</a>) shares dropped 32% to $4.52.</li>
<li>Shares of Baosheng Media Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) were down 42% to $4.14.</li>
<li>SaverOne 2014 Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) was down, falling 33% to $1.0148.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $69.98 while gold traded up 0.5% at $2,649.10.
Silver traded up 0.2% to $30.335 on Thursday, while copper rose 0.7% to $4.1375.
Euro zone
In Europe, markets in Germany, France, London, Spain and Switzerland are closed for the Boxing Day holiday.
European shares were higher today. The eurozone's STOXX 600 gained 0.17%, Germany's DAX fell 0.18% and France's CAC 40 rose 0.14%. Spain's IBEX 35 Index rose 0.33%, while London's FTSE 100 rose 0.42%.
Asia Pacific Markets
Asian markets closed mostly higher on Thursday, with Japan's Nikkei 225 gaining 1.12%, China's Shanghai Composite Index gaining 0.14% and India's BSE Sensex falling 0.01%.
Economics
U.S. initial jobless claims fell by 1,000 from the previous week to a reading of 219,000 during the second week of December, compared to market estimates of 224,000.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42684254/top-3-utilities-stocks-youll-regret-missing-in-december">Top 3 Utilities Stocks You&#8217;ll Regret Missing In December</a></li>
</ul>

Equities

Eurozone

Commodities

BAOS

LAES

NEUP

SVRE

ZCAR

S&P 500 Edges Lower, SciSparc Shares Surge

Paylocity Holding's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NYSE">PCTY</a>) short percent of float has fallen 25.09% since its last report. The company recently reported that it has 925 thousand shares sold short, which is 2.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Paylocity Holding Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735241421_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Paylocity Holding has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Paylocity Holding's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Paylocity Holding's peer group average for short interest as a percentage of float is 5.68%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PCTY

Looking Into Paylocity Holding's Recent Short Interest

First Solar's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NYSE">FSLR</a>) short percent of float has risen 27.67% since its last report. The company recently reported that it has 8.10 million shares sold short, which is 9.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.81 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>First Solar Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735241416_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for First Solar has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing First Solar's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, First Solar's peer group average for short interest as a percentage of float is 4.68%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FSLR

Peering Into First Solar's Recent Short Interest

Summit Materials's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) short percent of float has risen 49.37% since its last report. The company recently reported that it has 5.16 million shares sold short, which is 4.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Summit Materials Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735241410_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Summit Materials has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Summit Materials's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Summit Materials's peer group average for short interest as a percentage of float is 2.42%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Summit Materials's Recent Short Interest

<a href="https://downdetector.com/status/openai/" title="https://downdetector.com/status/openai/">https://downdetector.com/status/openai/</a>

MSFT

Downdetector Says User Reports Indicate Problems At OpenAi; ChatGPT, API, And Sora Is Currently Experiencing High Error Rates, Issue Caused By An Upstream Provider

An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in the battle between two health care companies seeing revenue growth and soaring stock prices as interest in <a href="https://www.benzinga.com/topic/weight-loss-drug">weight-loss drugs grows.</a>
What Happened: A post from Musk on Christmas shared his latest take on weight-loss drugs and could provide a suggestion to anyone<a href="https://www.benzinga.com/24/12/42291702/obesity-drug-wars-heat-up-amgen-challenges-eli-lilly-novos-dominance"> trying to decide</a> between Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro and Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic for weight-loss treatment.
The <a href="https://x.com/elonmusk/status/1872086971557761348">post </a>from Musk called himself "Ozempic Santa." Despite the post labeled with Ozempic, Musk admitted in the comments that it is actually Mounjaro that he has taken for weight-loss support.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Ozempic Santa <a href="https://t.co/7YECSNpWoz">pic.twitter.com/7YECSNpWoz</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1872086971557761348?ref_src=twsrc%5Etfw">December 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"Technically, Mounjaro, but that doesn't have the same ring to it," Musk tweeted.
Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also increasing in popularity as weight-loss options for people around the world.
When it comes to the two weight-loss drug options, Musk shared his personal takes on both.
"High doses of Ozempic made me fart &amp; burp like Barney from The Simpson's. Mounjaro seems to have fewer side effects and be more effective," Musk said.
With the Christmas posts, Musk has now shared publicly that he has tried Mounjaro, Ozempic and Wegovy, another treatment from Novo Nordisk.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/general/social-media/24/12/42490690/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Musk's Christmas post, continues his public support for weight-loss drugs.
After &#8220;South Park&#8221; aired a special mocking weight-loss drugs as a luxury for the wealthy, the billionaire<a href="https://www.benzinga.com/news/24/05/39019043/elon-musk-says-ozempic-will-become-very-cheap-after-new-comedy-special-paints-it-as-weight-loss-drug"> predicted these medications</a> would become more affordable over time.
In May, responding to a post about childhood obesity, <a href="https://www.benzinga.com/news/24/05/38634420/ozempic-ftw-elon-musk-touts-novo-nordisks-blockbuster-drug-as-solution-to-childhood-obesity-problem">Musk signaled support</a> for weight-loss medications by posting &#8220;Ozempic ftw&#8221; (for the win), suggesting these drugs could be a future tool against the epidemic.
The billionaire's future battle <a href="https://www.benzinga.com/general/health-care/24/12/42607280/elon-musk-vs-rfk-jr-obesity-crisis-debate-sparks-struggle-for-trumps-influence">could be convincing</a> Robert F. Kennedy Jr. and Donald Trump that Americans need more access to affordable weight-loss drugs like Mounjaro. Musk is arguing for more access while Kennedy, who Trump said will be nominated to lead the Health and Human Services, supports healthier eating to fight obesity.
NVO, LLY Price Action: Novo Nordisk stock trades at $87.56 at the time of writing. The stock is down 14% year-to-date in 2024 and up 200.6% over the last five years.
Eli Lilly stock trades at $795.87 at the time of writing. The stock is up 34% year-to-date in 2024 and up 504.7% over the last five years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41036415/eli-lilly-stock-soars-in-2024-on-weight-loss-drug-success-now-the-company-wants-medical-records-o">Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments</a></li>
</ul>
Photo: Shutterstock

Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?

President-elect Donald Trump&#8216;s second term could provide for-profit prisons an economic and regulatory boon amid Trump&#8217;s plans to <a href="https://www.benzinga.com/news/24/09/40744471/trumps-plan-to-ban-mortgages-for-undocumented-immigrants-sparks-debate-what-do-the-numbers-say">deport people living in the country illegally</a>.
Private Prisons: Corecivic Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXW#NYSE">CXW</a>) and Geo Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) are the two largest private prison operators in the United States.
Geo Group owns 50 facilities and 64,502 beds across the U.S. concentrated in the South and Southwest. In 2023, CoreCivic operated 43 facilities with approximately 65,000 beds, according to company filings. The facilities include migrant detention centers and minimum-to-medium security prisons.
Private prisons are a topic of debate given their for-profit nature and alleged human rights abuses. <a href="https://news.uchicago.edu/story/us-prison-labor-programs-violate-fundamental-human-rights-new-report-finds">According</a> to the University of Chicago Law School, labor conditions in private prisons are poor. The majority of prisoners are forced to work, often for wages under a dollar per hour, or face solitary confinement or loss of visitation rights. The report found that prisoners produce at least $2 billion annually in goods and over $9 billion in maintenance services.
In August 2016, then-President Barack Obama announced a plan to reduce and eliminate the use of private prisons in the U.S. Following Trump&#8217;s inauguration for his first term in 2017, Attorney General Jeff Sessions rescinded Obama&#8217;s memorandum, <a href="https://www.bop.gov/resources/news/pdfs/20170224_doj_memo.pdf">saying</a> the decision &#8220;impaired the Bureau&#8217;s ability to meet the future needs of the federal correctional system.&#8221; The stock prices of Geo and CoreCivic subsequently rallied over 30%.
As of July 2024, there <a href="https://homeland.house.gov/wp-content/uploads/2024/09/24-01143-ICEs-Signed-Response-to-Representative-Tony-Gonzales.pdf">were</a> 662,566 &#8220;noncitizens&#8221; with criminal histories on ICE's national docket, which includes those detained by ICE and on the agency's non-detained docket. Of those, 435,719 are convicted criminals and 226,847 have pending criminal charges.
Trump&#8217;s Immigration Plan: Future immigration enforcement, an issue Trump made central to his 2016, 2020, and 2024 campaigns, would require detention centers, perhaps operated by Geo and CoreCivic.
The ACLU <a href="https://wp.api.aclu.org/news/immigrants-rights/unchecked-growth-private-prison-corporations-and-immigration-detention-three-years-into-the-biden-administration">found</a> in 2023 that over 90% of migrants detained by ICE were held in privately owned facilities.
In a CNN <a href="https://www.cnn.com/2024/12/18/politics/border-czar-homan-trump-deportation-plans/index.html">interview</a>, Tom Homan, Trump&#8217;s incoming border czar, said the government needs a minimum of 100,000 beds to carry out Trump&#8217;s immigration plan. This represents a more than 100% increase over current capacity. He also elaborated on the extent to which Trump will carry out deportation.
"I don't have a number. We want to arrest as many people as we can that are in the country illegally," Homan said. "If you're here illegally, you're not off the table. It's a violation of the law; it's a crime to enter this country illegally."
The American Immigration Council, a pro-immigration advocacy group, <a href="https://www.americanimmigrationcouncil.org/research/mass-deportation">says</a> there were around 11 million people living in the U.S. illegally in 2022, roughly 3% of the country&#8217;s population. The council estimates that a deportation plan would cost at least $315 billion.
Why it Matters: Geo Group and CoreCivic also appear to be preparing for the future demand for detention centers. On Dec. 16, Geo Group announced a $70 million capital expenditure plan to expand ICE service capabilities.
In September, short-seller Andrew Left <a href="https://citronresearch.com/wp-content/uploads/2024/09/Geo-Group-093024.pdf">called</a> Geo Group the &#8220;default play&#8221; for a Trump presidency given his positions on immigration enforcement.
The market at large also seems convinced. Geo Group&#8217;s stock has risen over 86% since election day, while CoreCivic&#8217;s stock has risen over 58%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42679657/el-erian-explains-why-us-economy-is-likely-to-continue-outperforming-other-major-economies-in-2025">El Erian Explains Why US Economy Is &#8216;Likely To Continue Outperforming Other Major Economies In 2025&#8217;</a></li>
</ul>
Photo via Shutterstock.

Government

Politics

CoreCivic, Geo Group Rally By Double Digits Since Election Day: Why Trump Boosts Private Prison Stocks

‘Dogecoin Killer' Shiba Inu's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) relatively flat performance over the past week has not stopped <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42173367/shiba-inu-burn-rate-soars-487-in-a-day-what-is-going-on">its burn rates from increasing</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002167</td>
<td>$12.8 billion</td>
<td>-5.2%</td>
<td>&nbsp;-2.2%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.314</td>
<td>$46.3 billion</td>
<td>-5%&nbsp;</td>
<td>-1.5%&nbsp;</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00001743&nbsp;&nbsp;</td>
<td>$7.3 billion</td>
<td>&nbsp;-5.5%</td>
<td>&nbsp;-1.2%</td>
</tr>
</tbody>
</table>
</figure>
Technical Analysis: Benzinga technical analysis shows Shiba Inu's RSI is oversold at 28.6. This suggests that the price has fallen significantly over a short period, with potential for a price rebound or reversal.
Traders may interpret an RSI below 30 as a signal to look for a buying opportunity, expecting the price to recover soon. However, technical indicators do not predict price action.
Meanwhile, the 200-day simple moving average is below the 50-day and 100-day SMAs, implying a transition from a downtrend to an uptrend. It indicates that the longer-term average price (200-day) is beginning to align with recent upward momentum, suggesting potential for sustained bullishness.
Statistics: Shibburn data shows the ecosystem burned 20.9 million SHIB in the past 24 hours, pushing the burn rate higher by 2,227.6%. 
Around 19 hours ago, a single transaction involved the burning of 13.1 million SHIB and around four hours ago, a single transaction burned 1 million SHIB coins.
Whale Alert data <a href="https://x.com/whale_alert/status/1871955035837321658">shows</a> 2.88 trillion SHIB transferred from a Turkish exchange to an unknown wallet. 
BtcTurk responded that these transfers are part of wallet optimization efforts and fully managed by them, and there is nothing out of the ordinary.
IntoTheBlock data shows large transaction volume increasing by 169.9% in a single day. Shibariumscan data shows daily transactions spiked from 4.51 million to 4.74 million in a single day.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42679813/shytoshi-kusama-celebrates-as-shibainus-virtual-world-shib-the-metaverse-goes-live-on-christmas">Shytoshi Celebrates As Shiba Inu Virtual World &#8216;Shib The Metaverse&#8217; Goes Live On Christmas</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Shiba Inu Burn Rate Spikes 2,227%: What's Going On?

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares are trading lower Thursday driven by a Bitcoin pullback and investor reaction to the company's plans to issue additional shares to <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42684275/microstrategy-portland-general-electric-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session">fund further Bitcoin purchases.</a>
What To Know: In a filing with the SEC, the company proposed increasing its authorized Class A common stock from 330 million to 10.33 billion units and preferred stock from 5 million to over 1 billion units. This move is intended to support the company's strategy of accumulating Bitcoin, a cornerstone of its transition from software to cryptocurrency investment.
Bitcoin's recent volatility, with a peak near $100,000 and subsequent fluctuations, has added pressure on MicroStrategy's stock. The company recently acquired $561 million worth of Bitcoin, bringing its total holdings to approximately $40 billion. However, its aggressive Bitcoin purchases and reliance on stock issuance to fund acquisitions have drawn investor scrutiny.
MicroStrategy shares have faced significant challenges, including a more than 37% decline from their all-time high and an 8.5% drop following their inclusion in the Nasdaq 100. The ongoing stock issuance and Bitcoin market volatility continue to weigh on investor sentiment.
MSTR Price Action: MicroStrategy shares were down 4.16% at $343.06 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="526" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32-1024x526.png" alt="" class="wp-image-707953" style="width:448px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32-1024x526.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32-768x394.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32-1536x789.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42689962/a-billionaire-set-us-up-perfectly-for-this-options-trade">A Billionaire Set Us Up Perfectly for This Options Trade</a></li>
</ul>
Image Via Shutterstock.

MSTR

MicroStrategy Shares Are Falling Today: What's Going On?

Whales with a lot of money to spend have taken a noticeably bearish stance on Amentum Holdings.
Looking at options history for Amentum Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $62,908 and 10, calls, for a total amount of $599,620.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $25.0 for Amentum Holdings during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Amentum Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Amentum Holdings's substantial trades, within a strike price spectrum from $20.0 to $25.0 over the preceding 30 days.
<h3>Amentum Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735240536_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMTM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.7</td>
<td>$2.6</td>
<td>$2.7</td>
<td>$25.00</td>
<td>$135.0K</td>
<td>4.9K</td>
<td>2.4K</td>
</tr>
<tr>
<td>AMTM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.75</td>
<td>$2.65</td>
<td>$2.7</td>
<td>$25.00</td>
<td>$112.8K</td>
<td>4.9K</td>
<td>2.9K</td>
</tr>
<tr>
<td>AMTM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.5</td>
<td>$2.2</td>
<td>$2.35</td>
<td>$25.00</td>
<td>$58.7K</td>
<td>4.9K</td>
<td>1.6K</td>
</tr>
<tr>
<td>AMTM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.5</td>
<td>$2.2</td>
<td>$2.35</td>
<td>$25.00</td>
<td>$58.7K</td>
<td>4.9K</td>
<td>1.3K</td>
</tr>
<tr>
<td>AMTM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.5</td>
<td>$2.35</td>
<td>$2.35</td>
<td>$25.00</td>
<td>$58.7K</td>
<td>4.9K</td>
<td>771</td>
</tr>
</tbody>
</table>

<h3>About Amentum Holdings</h3>
Amentum Holdings Inc is engaged in engineering and technology solutions. The United States and its allies trust it to address their technical and complex scientific, security, and sustainability challenges.
Following our analysis of the options activities associated with Amentum Holdings, we pivot to a closer look at the company's own performance.
<h3>Current Position of Amentum Holdings</h3>
<ul>
<li>With a volume of 1,039,781, the price of AMTM is up 1.97% at $20.2. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 132 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amentum Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

AMTM

Check Out What Whales Are Doing With AMTM

Whales with a lot of money to spend have taken a noticeably bearish stance on Zscaler.
Looking at options history for Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) we detected 21 trades.
If we consider the specifics of each trade, it is accurate to state that 9% of the investors opened trades with bullish expectations and 80% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $128,915 and 19, calls, for a total amount of $1,446,125.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $145.0 and $220.0 for Zscaler, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Zscaler's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Zscaler's whale trades within a strike price range from $145.0 to $220.0 in the last 30 days. 
<h3>Zscaler 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735240532_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$7.2</td>
<td>$7.05</td>
<td>$7.05</td>
<td>$145.00</td>
<td>$97.9K</td>
<td>0</td>
<td align="right">140</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$48.25</td>
<td>$47.9</td>
<td>$47.9</td>
<td>$150.00</td>
<td>$91.0K</td>
<td>2.7K</td>
<td align="right">92</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$48.05</td>
<td>$47.75</td>
<td>$47.75</td>
<td>$150.00</td>
<td>$90.7K</td>
<td>2.7K</td>
<td align="right">20</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$47.8</td>
<td>$47.5</td>
<td>$47.5</td>
<td>$150.00</td>
<td>$90.2K</td>
<td>2.7K</td>
<td align="right">158</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$47.7</td>
<td>$47.4</td>
<td>$47.4</td>
<td>$150.00</td>
<td>$90.0K</td>
<td>2.7K</td>
<td align="right">111</td>
</tr>
</tbody>
</table>

<h3>About Zscaler</h3>
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
Having examined the options trading patterns of Zscaler, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Zscaler</h3>
<ul>
<li>With a volume of 373,425, the price of ZS is down -0.66% at $186.03. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 63 days.</li>
</ul>
<h3>Expert Opinions on Zscaler</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $229.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Zscaler, targeting a price of $240. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Zscaler, targeting a price of $235. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Zscaler, maintaining a target price of $190. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for Zscaler, targeting a price of $250. 
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Zscaler with a target price of $230. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Zscaler with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on Zscaler Options

Deep-pocketed investors have adopted a bullish approach towards Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in OXY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 19 extraordinary options activities for Occidental Petroleum. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 68% leaning bullish and 21% bearish. Among these notable options, 11 are puts, totaling $419,286, and 8 are calls, amounting to $345,970.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $57.5 for Occidental Petroleum during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Occidental Petroleum options trades today is 2391.0 with a total volume of 10,631.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Occidental Petroleum's big money trades within a strike price range of $35.0 to $57.5 over the last 30 days.
<h3>Occidental Petroleum Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735240527_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.4</td>
<td>$9.3</td>
<td>$9.3</td>
<td>$57.50</td>
<td>$67.8K</td>
<td>1.0K</td>
<td align="right">74</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$50.00</td>
<td>$61.0K</td>
<td>5.0K</td>
<td align="right">851</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.05</td>
<td>$2.92</td>
<td>$3.0</td>
<td>$50.00</td>
<td>$60.0K</td>
<td>5.0K</td>
<td align="right">236</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.05</td>
<td>$2.93</td>
<td>$2.95</td>
<td>$50.00</td>
<td>$59.0K</td>
<td>5.0K</td>
<td align="right">640</td>
</tr>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.95</td>
<td>$6.8</td>
<td>$6.85</td>
<td>$55.00</td>
<td>$45.2K</td>
<td>9.9K</td>
<td align="right">66</td>
</tr>
</tbody>
</table>

<h3>About Occidental Petroleum</h3>
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1,234 thousand barrels of oil equivalent per day in 2023 at a ratio of roughly 50% oil and natural gas liquids and 50% natural gas.
After a thorough review of the options trading surrounding Occidental Petroleum, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Occidental Petroleum Standing Right Now?</h3>
<ul>
<li>With a trading volume of 8,284,328, the price of OXY is up by 0.08%, reaching $48.16.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 48 days from now.</li>
</ul>
<h3>Expert Opinions on Occidental Petroleum</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $56.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Neutral rating on Occidental Petroleum with a target price of $70. 
&#x2A; An analyst from UBS persists with their Neutral rating on Occidental Petroleum, maintaining a target price of $51. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Occidental Petroleum, which currently sits at a price target of $53. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Occidental Petroleum, maintaining a target price of $51. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Occidental Petroleum, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Check Out What Whales Are Doing With OXY

WIIM

SBUX

Starbucks shares are trading higher following the end of a five-day barista strike.

Shares of Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) are rising Thursday but they have run into resistance around the $3.25 level. There is a chance this resistance breaks and the stock<a href="https://www.benzinga.com/tech/24/12/42668333/tesla-model-x-lucid-gravity-or-rivian-r1s-which-three-row-electric-suv-is-a-better-buy"> keeps moving higher.</a>
Breakouts tend to be bullish. This is why our team of traders has made Lucid our Stock of the Day.
Markets are always trending. They are either going up, down, or sideways. If a market is trending higher the bulls are in control. If it is heading lower, the bears are in charge. If they go sideways, the bears and bulls have equal strength.
Sometimes, when the leadership changes from bears to bulls or bulls to bears, the price action can appear on a chart as a reversal pattern.
If the change occurs in one day, a reversal day pattern may appear. If it takes place over a few days, a V or Inverted V pattern may show up.
Read Also: <a href="https://www.benzinga.com/tech/24/12/42668333/tesla-model-x-lucid-gravity-or-rivian-r1s-which-three-row-electric-suv-is-a-better-buy">Tesla Model X, Lucid Gravity Or Rivian R1S: Which Three-Row Electric SUV Is A Better Buy?</a>
If the change is slow and steady over an extended time, it may create a rounded top or rounded bottom pattern.
As you can see on the chart, a rounded bottom formed in Lucid. The bulls slowly took charge in November and the stock has been rallying since.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26135703/lcid-1-1024x571.png" alt="" class="wp-image-708021" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26135703/lcid-1-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26135703/lcid-1-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26135703/lcid-1-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26135703/lcid-1.png 1459w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
There is resistance at the $3.25 level because it was previously support. Resistance forming at prices that had been support is a common occurrence in the stock market. It happens because of buyer's remorse.
There are traders and investors who purchased shares while they were at support who came to regret doing so when the support broke and the price moved lower. A number of these remorseful buyers decided to exit their positions if they can do so at breakeven.
As a result, now that the stock has rallied back to their buying prices, they are placing sell orders. This has caused resistance to form at the level that had been support.
If the stock gets above and stays above this resistance, traders will call it a breakout. This is a bullish dynamic because it shows that the sellers who created the resistance are out of the way. They have finished or canceled their orders.
This may set the stage for a move higher. Buyers will need to bid premiums to draw sellers back into the market. This could force the stock into a new uptrend and that may be about to happen with <a href="https://www.benzinga.com/quote/LCID">Lucid</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42688941/are-us-vehicles-under-30000-a-thing-of-the-past-trumps-mexico-tariff-plans-could-change-auto-market#google_vignette">Are Sub-$30,000 Cars Disappearing? Trump&#8217;s Tariff Plans Could Reshape US Auto Market</a></li>
</ul>
Photo by Mike Mareen on Shutterstock.

Technicals

Tech

Stock Of The Day: Lucid Momentum Builds As Bears Lose Their Grip

Investors with a lot of money to spend have taken a bullish stance on Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DAL, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for Delta Air Lines.
This isn't normal.
The overall sentiment of these big-money traders is split between 60% bullish and 35%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $211,223, and 16 are calls, for a total amount of $680,559.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $90.0 for Delta Air Lines during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Delta Air Lines's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Delta Air Lines's significant trades, within a strike price range of $35.0 to $90.0, over the past month.
<h3>Delta Air Lines 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735239637_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$8.9</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$57.50</td>
<td>$100.3K</td>
<td>1.6K</td>
<td align="right">114</td>
</tr>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.18</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$65.00</td>
<td>$75.1K</td>
<td>46.6K</td>
<td align="right">403</td>
</tr>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.65</td>
<td>$7.45</td>
<td>$7.45</td>
<td>$60.00</td>
<td>$74.5K</td>
<td>967</td>
<td align="right">100</td>
</tr>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.9</td>
<td>$67.50</td>
<td>$70.3K</td>
<td>1.0K</td>
<td align="right">348</td>
</tr>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.65</td>
<td>$7.4</td>
<td>$7.45</td>
<td>$60.00</td>
<td>$67.0K</td>
<td>967</td>
<td align="right">190</td>
</tr>
</tbody>
</table>

<h3>About Delta Air Lines</h3>
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.
In light of the recent options history for Delta Air Lines, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Delta Air Lines Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,173,331, the DAL's price is up by 0.12%, now at $62.63. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 15 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Delta Air Lines with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

A Closer Look at Delta Air Lines's Options Market Dynamics

Investors with a lot of money to spend have taken a bullish stance on IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IBM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 18 uncommon options trades for IBM.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 27%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $365,840, and 12 are calls, for a total amount of $619,814.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $175.0 to $250.0 for IBM over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in IBM's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to IBM's substantial trades, within a strike price spectrum from $175.0 to $250.0 over the preceding 30 days.
<h3>IBM Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735239632_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$9.75</td>
<td>$9.55</td>
<td>$9.55</td>
<td>$220.00</td>
<td>$167.1K</td>
<td>2.1K</td>
<td align="right">0</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$52.7</td>
<td>$50.3</td>
<td>$50.87</td>
<td>$175.00</td>
<td>$127.1K</td>
<td>3.5K</td>
<td align="right">25</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/10/25</td>
<td>$8.8</td>
<td>$8.55</td>
<td>$8.78</td>
<td>$217.50</td>
<td>$87.7K</td>
<td>0</td>
<td align="right">100</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$40.7</td>
<td>$40.25</td>
<td>$40.7</td>
<td>$185.00</td>
<td>$77.3K</td>
<td>1.5K</td>
<td align="right">1</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$36.05</td>
<td>$35.3</td>
<td>$35.75</td>
<td>$190.00</td>
<td>$53.6K</td>
<td>4.9K</td>
<td align="right">15</td>
</tr>
</tbody>
</table>

<h3>About IBM</h3>
IBM looks to be a part of every aspect of an enterprise's IT needs. The company primarily sells software, IT services, consulting, and hardware. IBM operates in 175 countries and employs approximately 350,000 people. The company has a robust roster of 80,000 business partners to service 5,200 clients, which includes 95% of all Fortune 500. While IBM is a B2B company, IBM's outward impact is substantial. For example, IBM manages 90% of all credit card transactions globally and is responsible for 50% of all wireless connections in the world.
Having examined the options trading patterns of IBM, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is IBM Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,512,311, the price of IBM is up by 0.14%, reaching $224.73.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 34 days from now.</li>
</ul>
<h3>What Analysts Are Saying About IBM</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $222.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on IBM, which currently sits at a price target of $222. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for IBM, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Smart Money Is Betting Big In IBM Options

Investors with a lot of money to spend have taken a bearish stance on Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RGTI, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 59 uncommon options trades for Rigetti Computing.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 42%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $352,808, and 50 are calls, for a total amount of $2,659,299.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $2.5 and $25.0 for Rigetti Computing, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Rigetti Computing's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Rigetti Computing's whale trades within a strike price range from $2.5 to $25.0 in the last 30 days. 
<h3>Rigetti Computing Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735239627_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/03/25</td>
<td>$1.65</td>
<td>$1.55</td>
<td>$1.64</td>
<td>$14.50</td>
<td>$290.5K</td>
<td>38</td>
<td>2.7K</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$7.1</td>
<td>$6.7</td>
<td>$6.7</td>
<td>$7.50</td>
<td>$184.3K</td>
<td>7.6K</td>
<td>1.1K</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.5</td>
<td>$7.2</td>
<td>$7.28</td>
<td>$7.50</td>
<td>$145.6K</td>
<td>7.3K</td>
<td>848</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.8</td>
<td>$5.5</td>
<td>$5.71</td>
<td>$7.50</td>
<td>$114.2K</td>
<td>7.3K</td>
<td>249</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.5</td>
<td>$7.2</td>
<td>$7.28</td>
<td>$7.50</td>
<td>$110.6K</td>
<td>7.3K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Rigetti Computing</h3>
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, it derives a majority of its revenue from the United States.
Having examined the options trading patterns of Rigetti Computing, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Rigetti Computing's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 160,590,316, the RGTI's price is up by 27.6%, now at $14.48. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<h3>Expert Opinions on Rigetti Computing</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $12.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Craig-Hallum lowers its rating to Buy with a new price target of $12.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Rigetti Computing with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

RGTI

Smart Money Is Betting Big In RGTI Options

Throughout the last three months, 14 analysts have evaluated Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $245.14, with a high estimate of $325.00 and a low estimate of $184.00. A decline of 0.04% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1735239609_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Apple among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$273.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$273.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Tom Forte</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Hold</td>
<td>$215.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$184.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$262.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brandon Nispel</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Underweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Kyle Mcnealy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$212.92</td>
<td>$205.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$256.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$186.00</td>
<td>$186.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apple. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Apple compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Apple's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Apple's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Apple analyst ratings.</a>
<h2>Delving into Apple's Background</h2>
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
<h3>Understanding the Numbers: Apple's Finances</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Apple's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.07%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Apple's net margin excels beyond industry benchmarks, reaching 15.52%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Apple's ROE stands out, surpassing industry averages. With an impressive ROE of 23.83%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Apple's ROA stands out, surpassing industry averages. With an impressive ROA of 4.23%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 1.87, Apple faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

AAPL

What 14 Analyst Ratings Have To Say About Apple

Laser Photonics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) stock is trading higher on Thursday after the company announced it <a href="https://www.benzinga.com/pressreleases/24/12/b42681379/laser-photonics-scores-order-from-walsh-service-solutions">received an order</a> from Walsh Service Solutions.
The Details: Walsh placed an order for the CleanTech IR-3040 which is a handheld fiber laser system designed by Laser for speedy surface decontamination.
It plans to utilize the CleanTech IR-3040 in the abatement and remediation of inland waterway infrastructure including canal locks.
Walsh said, &#8220;We selected Laser Photonics&#8217; CleanTech IR-3040 for the safety, versatility, and efficiency it will bring to our specific applications in this project and many others.&#8221;
John Armstrong, the Executive Vice President of LPC, stated, &#8220;We are thrilled that Walsh Service Solutions has selected Laser Photonics as its supplier of laser cleaning equipment for its critical project. It is essential that maintenance projects near waterways do not harm local ecosystems. This is where laser technology excels, as it eliminates the need for abrasives and chemicals, leaving no mess behind.&#8221;
See Also: <a href="https://www.benzinga.com/insights/options/24/12/42690544/10-industrials-stocks-with-whale-alerts-in-todays-session">10 Industrials Stocks With Whale Alerts In Today&#8217;s Session</a>
LASE Price Action: At the time of publication, Laser shares are trading 24.6% higher at $7.05, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Pexels/ Tima Miroshnichenko

LASE

What's Going On With Laser Photonics Shares Thursday?

Editor&#8217;s note: The headline of this story has been corrected to state that SEALSQ Corp shares are rising. 
U.S. stocks turned higher midway through trading, with the Dow Jones index gaining around 50 points on Thursday.
The Dow traded up 0.12% to 43,347.41 while the NASDAQ rose 0.03% to 20,037.71. The S&amp;P 500 also rose, gaining, 0.05% to 6,042.96.
Check This Out: <a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Health care shares rose by just 0.1% on Thursday.
In trading on Thursday, information technology shares dipped by 0.4%.
Top Headline
U.S. initial jobless claims fell by 1,000 from the previous week to a reading of 219,000 during the second week of December, compared to market estimates of 224,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares shot up 31% to $7.16. On Thursday, SEALSQ announced the launch of SEALQUANTUM.com Lab, a research hub designed to help businesses transition to quantum-safe encryption</li>
<li>Shares of SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>)got a boost, surging 155% to $0.5600 after the company announced it received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) shares were also up, gaining 90% to $2.71 after it reported a 43% year-on-year increase in November bookings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Neuphoria Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEUP#NASDAQ">NEUP</a>) shares dropped 38% to $4.10.</li>
<li>Shares of Baosheng Media Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) were down 34% to $4.66.</li>
<li>SaverOne 2014 Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) was down, falling 30% to $1.0501.</li>
</ul>
Commodities In commodity news, oil traded up 0.2% to $70.25 while gold traded up 0.6% at $2,651.20.
Silver traded up 0.6% to $30.450 on Thursday, while copper rose 0.6% to $4.1335.
Euro zone
In Europe, markets in Germany, France, London, Spain and Switzerland are closed for the Boxing Day holiday.
Asia Pacific Markets
Asian markets closed mostly higher on Thursday, with Japan's Nikkei 225 gaining 1.12%, China's Shanghai Composite Index gaining 0.14% and India's BSE Sensex falling 0.01%.
Economics
U.S. initial jobless claims fell by 1,000 from the previous week to a reading of 219,000 during the second week of December, compared to market estimates of 224,000.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42684254/top-3-utilities-stocks-youll-regret-missing-in-december">Top 3 Utilities Stocks You&#8217;ll Regret Missing In December</a></li>
</ul>

Dow Gains 50 Points, SEALSQ Shares Rally (CORRECTED)

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA, a biotech company based in Milan, is focused on the research,...

Genenta Science Advances Biotech Endeavors

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cingulate Inc (CING – Research Report) and Genenta...

Analysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;



Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.



Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.



Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;



One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Nuvectis Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvct-stock-quote/">NVCT</a>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.



Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;



The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Relmada Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/">RLMD</a>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.



REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.



The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;



Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div>Anixa Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/anix-stock-quote/">ANIX</a>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;



The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;



The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Let&rsquo;s begin discussing Genenta Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnta-stock-quote/">GNTA</a>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.



While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.



The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div>Affimed (NASDAQ:<a href="https://investorplace.com/stock-quotes/afmd-stock-quote/">AFMD</a>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.



The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.



AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;



As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Lipocine (NASDAQ:<a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/">LPCN</a>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.



As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.



However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;



What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.



On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> Publishing Guidelines.</a>
<div>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Penny Biotech Stocks to Triple Your Investment

Maxim Group analyst Jason McCarthy maintained a Buy rating on Genenta Science SpA Sponsored ADR (GNTA – Research Report) yesterday and set a price ...

Buy Rating Affirmed for Genenta Science Amid Promising Developments in Gene Therapy Trials

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR – Research Report) and Genenta Science SpA Sponsored...

Analysts Offer Insights on Healthcare Companies: Danaher (DHR) and Genenta Science SpA Sponsored ADR (GNTA)

09:35 EDT Genenta Science (GNTA) SPA (ADR) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...

Genenta Science SPA (ADR) trading resumes

Genenta Science (GNTA) announced that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting "Cross-Border Investments and Str...

Genenta Science CEO to present at U.S. Senate meeting

09:40 EST Genenta Science (GNTA) SPA (ADR) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...

09:30 EST Genenta Science (GNTA) SPA (ADR) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, ...

Genenta Science SPA (ADR) trading halted, volatility trading pause

An update from Genenta Science SpA Sponsored ADR ( ($GNTA) ) is now available. Genenta Science S.p.A. has announced an amendment to its ATM Sales A...

Genenta Science Updates ATM Sales Agreement with New Agent

AFMD

ANIX

CING

FGEN

LPCN

NVCT

RLMD

Health Care

Press Releases

General

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Management

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective"

ARYD

Comments

Genenta Science

Genenta Science (GNTA) Forecast

Genenta Science (NASDAQ:GNTA) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga